NPC 21
Alternative Names: NPC 21Latest Information Update: 23 Feb 2023
Price :
$50 *
At a glance
- Originator Nobelpharma
- Developer Evec; Nobelpharma
- Class Antibodies; Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cytomegalovirus infections
Most Recent Events
- 08 Feb 2023 Nobelpharma completes a Phase-II clinical trials in Cytomegalovirus infections (Prevention) in USA (IV) (NCT04225923)
- 14 Oct 2022 Nobelpharma anticipates regulatory approval for Cytomegalovirus infections in December 2027 (Nobelpharma pipeline, October 2022)
- 28 May 2022 No recent reports of development identified for phase-I development in Cytomegalovirus infections in Japan (IV, Infusion)